Webinar
Hatch-Waxman 201
Hosts
-
- Name
- Person title
- Principal
-
- Name
- Person title
- Associate
-
- Name
- Person title
- Associate
For branded drug companies, the development of a hit pharmaceutical product all but assures generic competition. As discussed during the first installment in our 2024 Hatch-Waxman webinar series, “Hatch-Waxman 101,” disputes between branded and generic drug makers are governed by the Hatch-Waxman Act, which attempts to strike a balance between the pharmaceutical industry's need to protect its innovations and the public's need for affordable drugs. But that balance is delicate, and Hatch-Waxman litigation is among the most complex and high-stakes legal endeavors most drug makers will pursue.
On September 12, please join attorneys Megan Chacon, Madelyn McCormick, and Evan Sumner for "Hatch-Waxman 201," a deeper dive into the Hatch-Waxman Act and the legal considerations surrounding it. Our hosts will cover the following topics:
- Challenges to drug exclusivities
- Orange Book strategies
- Infringement issues every Hatch-Waxman litigant should know
- Using real-world facts in Hatch-Waxman litigation
We hope you will join us!
For more information about Hatch-Waxman litigation, please see our previous webinars "Hatch-Waxman 101" and "Preparing Your Company for Hatch-Waxman."
Fish & Richardson will apply for 1.0 hour of CLE credit.
If you have any questions, please contact [email protected].